BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ViiV Healthcare readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ViiV Healthcare's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07202546-978@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:VH4524184: Phase 2 readout est. (NCT07202546)
DESCRIPTION:VH4524184\, phase 2\, HIV.\nStudy: A Phase 2b Study Evaluating 
 Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE S
 tudy)\nEstimated primary completion: 28 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vh4524184#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07202546
URL:https://assetmemo.bio/drug/vh4524184#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134362-11050@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20290314
DTEND;VALUE=DATE:20290315
SUMMARY:Cabotegravir (Apretude): Phase 3 readout est. (NCT06134362)
DESCRIPTION:Cabotegravir (Apretude)\, phase 3\, HIV.\nStudy: Long-term Foll
 ow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophyla
 xis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Viru
 s)\nEstimated primary completion: 14 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06134362
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650916-957@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 3 readout est. (NCT07650
 916)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 3\, HIV.\nStudy: A 
 Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivi
 rine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Ar
 e Virologically Suppressed\nEstimated primary completion: 13 August 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivir
 ine-cabenuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07650916
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275606-957@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20291010
DTEND;VALUE=DATE:20291011
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 1/2 readout est. (NCT072
 75606)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 1/2\, HIV.\nStudy: 
 A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1\nEstimat
 ed primary completion: 10 October 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07275606
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816250-957@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20320610
DTEND;VALUE=DATE:20320611
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 2 readout est. (NCT07816
 250)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 2\, HIV.\nStudy: A 
 Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectabl
 e Plus Cabotegravir in Treatment Naïve Adults (CINERGY)\nEstimated primar
 y completion: 10 June 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07816250
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393659-963@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20320914
DTEND;VALUE=DATE:20320915
SUMMARY:Rukobia (Fostemsavir): Phase 3 readout est. (NCT07393659)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 3\, HIV.\nStudy: A Continued Acce
 ss Study for Participants Transitioning From ViiV Healthcare-sponsored or 
 ViiV Healthcare-collaborative Parent Studies for HIV Treatment\nEstimated 
 primary completion: 14 September 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fostemsavir#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07393659
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
